<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02345408</url>
  </required_header>
  <id_info>
    <org_study_id>CL002_872</org_study_id>
    <nct_id>NCT02345408</nct_id>
  </id_info>
  <brief_title>Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma</brief_title>
  <official_title>An Open-label Phase 1b Study to Evaluate the Safety and Efficacy of CCX872-B in Patients With Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ChemoCentryx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ChemoCentryx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label phase 1-b study to evaluate the safety and efficacy of CCX872-B in&#xD;
      patients with pancreatic adenocarcinoma also receiving FOLFIRINOX chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>subject incidence of Grade 3 or 4 adverse events</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>CCX872-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg once or twice daily given orally for at least 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CCX872-B</intervention_name>
    <description>Tablets (oral administration)</description>
    <arm_group_label>CCX872-B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-resectable pancreatic adenocarcinoma&#xD;
             with or without metastases&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2&#xD;
&#xD;
          -  Anticipated life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Radiographically measurable disease acc. to RECIST 1.1&#xD;
&#xD;
          -  Use of adequate contraception (as described in protocol)&#xD;
&#xD;
          -  Ability to provide written informed consent and comply with study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received other cancer treatment or investigational drug within 4 weeks prior to&#xD;
             screening&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Had major surgery within 4 weeks of first dose of study drug&#xD;
&#xD;
          -  Inadequate liver, renal or bone marrow function within 2 weeks of first dose&#xD;
&#xD;
          -  Serious concurrent illness, altered medical status or any uncontrolled medical&#xD;
             condition&#xD;
&#xD;
          -  Any infection requiring antibiotic or anti-viral treatment within 4 weeks of screening&#xD;
&#xD;
          -  Known active HIV, HBV or HCV infection&#xD;
&#xD;
          -  Inability to swallow tablets&#xD;
&#xD;
          -  History or presence of any medical condition or disease which, in the opinion of the&#xD;
             investigator, may place the subject at unacceptable risk for study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherland</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 20, 2015</study_first_submitted>
  <study_first_submitted_qc>January 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>August 14, 2019</last_update_submitted>
  <last_update_submitted_qc>August 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

